Travere Therapeutics, INC Form 4 insider transactions

Travere Therapeutics Director Gary A. Lyons exercised stock options and immediately sold 8,000 shares for a profit under a pre-arranged 10b5-1 plan.

Director Roy D. Baynes exercised stock options and sold 32,750 shares of Travere Therapeutics, Inc. common stock.

SVP and Chief Accounting Officer Sandra Calvin exercised stock options and sold shares under a Rule 10b5-1 plan.

Chief Commercial Officer Peter Heerma acquired 14,000 shares via PSU vesting and sold 7,215 shares to cover tax obligations.

Chief Research Officer William E. Rote acquired 14,000 shares of Travere Therapeutics common stock following the FDA approval of FILSPARI.

CEO Eric Dube acquired 64,000 shares via PSU vesting and sold 64,000 shares to cover tax obligations.

Chief Legal Officer Elizabeth E. Reed reported the vesting of performance units and subsequent sale of shares to cover tax obligations.

Travere Therapeutics CFO Christopher R. Cline reported the vesting of performance-based stock units and subsequent mandatory tax-related share sales.

Chief Medical Officer Jula Inrig acquired 14,000 shares via PSU vesting and sold 8,233 shares to cover tax obligations.

Travere Therapeutics Director Roy D. Baynes reported a sale of 10,000 shares of common stock for $26.52 per share, executed under a Rule 10b5-1 trading plan.

Travere Therapeutics CEO Eric M. Dube reported the sale of 85,000 shares of common stock, acquired through stock options, under a pre-arranged trading plan.

Elizabeth E. Reed, Chief Legal Officer of Travere Therapeutics, sold 10,000 shares of common stock on April 1, 2026, as part of a pre-arranged 10b5-1 trading plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised options and sold 10,000 shares of common stock for a profit, pursuant to a pre-arranged 10b5-1 plan.

Travere Therapeutics CEO Eric Dube exercised stock options and sold 60,000 common shares for a profit, as per a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold common stock on February 4, 2026, under a pre-arranged 10b5-1 plan, including shares to cover tax obligations from vested restricted stock units.

Travere Therapeutics' CFO, Christopher R. Cline, sold common stock totaling 1,745 shares on February 4, 2026, under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, sold common stock totaling 2,994 shares on February 4, 2026, under a pre-arranged 10b5-1 plan.

Travere Therapeutics CEO Eric Dube reported the acquisition of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Travere Therapeutics' CFO, Christopher R. Cline, reported the acquisition of common stock and stock options, alongside a tax-related 'sell to cover' transaction.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, reported the acquisition of restricted stock units and stock options, alongside a 'sell to cover' transaction for tax obligations.

Travere Therapeutics' Chief Research Officer, William E. Rote, reported the acquisition of restricted stock units and stock options, alongside a sale of common stock to cover tax obligations.

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, reported the acquisition of restricted stock units and stock options, alongside a tax-related stock sale.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, reported the acquisition of restricted stock units and stock options, alongside a mandated 'sell to cover' transaction for tax obligations.

Travere Therapeutics CEO Eric M. Dube exercised 60,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 plan.

Elizabeth E. Reed, Travere Therapeutics' Chief Legal Officer, exercised stock options and sold 10,000 shares under a pre-arranged plan.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold common stock to cover tax withholding obligations related to vested restricted stock units, with one transaction also part of a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, sold 4,980 shares of common stock at $40 per share under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Research Officer, William E. Rote, exercised stock options and subsequently sold 60,000 shares of common stock for a profit, as detailed in a recent SEC Form 4 filing.